Hepatitis C New Drugs Review
25.5K views | +1 today
Follow
 
Scooped by Krishan Maggon
onto Hepatitis C New Drugs Review
Scoop.it!

Efficacy and safety of telaprevir (TVR) triple therapy in a real-life cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment

Infectious Disease Medical Article: Efficacy and safety of telaprevir (TVR) triple therapy in a real-life cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment (Efficacy and safety of telaprevir (TVR) triple...
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
Scooped by Krishan Maggon
Scoop.it!

Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma

Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma | Hepatitis C New Drugs Review | Scoop.it
Chaisaingmongkol et al. identify common molecular subtypes linked to similar prognosis
in intrahepatic cholangiocarcinoma and hepatocellular carcinoma, clinically different
malignancies, among Thai patients. These molecular subtypes are also found in other
Asian patients, but rarely in Caucasian patients.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries | Gilead

Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries | Gilead | Hepatitis C New Drugs Review | Scoop.it
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma

HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma | Hepatitis C New Drugs Review | Scoop.it
Kaplan-Meier curves of survival free of HCC by cirrhosis and SVR status after DAA-only
antiviral treatment: SVR is associated with a reduction in HCC risk both among patients
with cirrhosis and those without cirrhosis.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

An update on the management of chronic hepatitis B and C infection | Review article - Pharmacy Tech

An update on the management of chronic hepatitis B and C infection | Review article - Pharmacy Tech | Hepatitis C New Drugs Review | Scoop.it
Abstract: Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure.…
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094

Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094 | Hepatitis C New Drugs Review | Scoop.it
ABSTRACT Ribonucleoside analog inhibitors (rNAI) target the hepatitis C virus (HCV) RNA-dependent RNA polymerase nonstructural protein 5B (NS5B) and cause RNA chain termination. Here, we expand our studies on β-D-2′-C-methyl-2,6-diaminopurine-ribonucleotide (DAPN) phosphoramidate prodrug 1 (PD1) as a novel investigational inhibitor of HCV. DAPN-PD1 is metabolized intracellularly into two distinct bioactive nucleoside triphosphate (TP) analogs. The first metabolite, 2′-C-methyl-GTP, is a well-characterized inhibitor of NS5B polymerase, whereas the second metabolite, 2′-C-methyl-DAPN-TP, behaves as an adenosine base analog. In vitro assays suggest that both metabolites are inhibitors of NS5B-mediated RNA polymerization. Additional factors, such as rNAI-TP incorporation efficiencies, intracellular rNAI-TP levels, and competition with natural ribonucleotides, were examined in order to further characterize the potential role of each nucleotide metabolite in vivo. Finally, we found that although both 2′-C-methyl-GTP and 2′-C-methyl-DAPN-TP were weak substrates for human mitochondrial RNA (mtRNA) polymerase (POLRMT) in vitro, DAPN-PD1 did not cause off-target inhibition of mtRNA transcription in Huh-7 cells. In contrast, administration of BMS-986094, which also generates 2′-C-methyl-GTP and previously has been associated with toxicity in humans, caused detectable inhibition of mtRNA transcription. Metabolism of BMS-986094 in Huh-7 cells leads to 87-fold higher levels of intracellular 2′-C-methyl-GTP than DAPN-PD1. Collectively, our data characterize DAPN-PD1 as a novel and potent antiviral agent that combines the delivery of two active metabolites.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Improving Hepatitis C Identification: Technology Alone Is Not the Answer. - PubMed - NCBI

Improving Hepatitis C Identification: Technology Alone Is Not the Answer. - PubMed - NCBI | Hepatitis C New Drugs Review | Scoop.it
Health Promot Pract. 2017 Sep 1:1524839917725501. doi: 10.1177/1524839917725501. [Epub ahead of print]
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Janssen to Discontinue Hepatitis C Development Program | Johnson & Johnson

Janssen to Discontinue Hepatitis C Development Program | Johnson & Johnson | Hepatitis C New Drugs Review | Scoop.it
Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India

Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India | Hepatitis C New Drugs Review | Scoop.it
Background & aims Availability of directly-acting antivirals (DAAs) has changed the treatment landscape of hepatitis C virus (HCV) infection. The high price of DAAs has restricted their use in several countries. However, in some countries such as India, generic DAAs are available at much cheaper price. This study examined whether generic DAAs could be cost-saving and how long it would take for the treatment to become cost-saving/effective. Methods A previously-validated, mathematical model was adapted to the HCV-infected population in India to compare the outcomes of no treatment versus treatment with DAAs. Model parameters were estimated from published studies. Cost-effectiveness of HCV treatment using available DAAs was calculated, using a payer’s perspective. We estimated quality-adjusted life years (QALYs), disability-adjusted life years (DALYs), total costs, and incremental cost-effectiveness ratio of DAAs versus no treatment. One-way and probabilistic sensitivity analyses were conducted. Results Compared with no treatment, the use of generic DAAs in Indian HCV patients would increase the life expectancy by 8.02 years, increase QALYs by 3.89, avert 19.07 DALYs, and reduce the lifetime healthcare costs by $1,309 per-person treated. Treatment became cost-effective within 2 years, and cost-saving within 10 years of its initiation overall and within 5 years in persons with cirrhosis. Treating 10,000 HCV-infected persons could prevent 3400–3850 decompensated cirrhosis, 1800–2500 HCC, and 4000–4550 liver-related deaths. The results were sensitive to the costs of DAAs, pre- and post-treatment diagnostic tests and management of cirrhosis, and quality of life after sustained virologic response. Conclusions Treatment with generic DAAs available in India will improve patient outcomes, provide a good value for money within 2 years, and be ultimately cost-saving. Therefore, in this and similar settings, HCV treatment should be a priority from a public health as well an economic perspective.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market | Hepatitis C New Drugs Review | Scoop.it
After committing billions of dollars to a new hepatitis C cocktail that had the potential to compete with the already deeply entrenched rivals on the market, J&J is calling it quits. Drawn to hepatitis C at a time when the field was undergoing a dramatic shift in coming up with
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals | Read by QxMD

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals | Read by QxMD | Hepatitis C New Drugs Review | Scoop.it
BACKGROUND AND AIMS: Psychiatric or substance use disorders are barriers to successful HCV antiviral treatment. In a randomized, controlled trial (RCT), the effects of HCV Integrated Care (IC) for increasing treatment rates and sustained viral response (SVR) were studied with direct acting...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Virus II – Infection and Disease PDF

Hepatitis C Virus II – Infection and Disease PDF | Hepatitis C New Drugs Review | Scoop.it
Arslan Library is the ultimate source to Download Free Medical Books in PDF. This website has been designed especially for Medical Students & Doctors.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa - Volume 23, Number 9—September 2017 - Emerging Infectious Disease journal - CDC

Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa - Volume 23, Number 9—September 2017 - Emerging Infectious Disease journal - CDC | Hepatitis C New Drugs Review | Scoop.it
Among 397,640 first-time blood donors screened in South Africa during 2012–2015, HIV prevalence was 1.13%, hepatitis B virus prevalence 0.66%, and hepatitis C virus prevalence 0.03%. Findings of note were a high HIV prevalence in Mpumalanga Province and the near absence of hepatitis C virus nationwide.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features | Hepatitis C New Drugs Review | Scoop.it
Agents that induce an immune response against tumors by altering T-cell regulation
have increased survival times of patients with advanced-stage tumors, such as melanoma
or lung cancer. We aimed to characterize molecular features of immune cells that infiltrate
hepatocellular carcinomas (HCCs) to determine whether these types of agents might
be effective against liver tumors.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Diagnosis Seen as Biggest Bottleneck in Reaching Global Elimination

Hepatitis C Diagnosis Seen as Biggest Bottleneck in Reaching Global Elimination | Hepatitis C New Drugs Review | Scoop.it
Worldwide HCV prevalence in 2017 dropped 2% from 2015 levels to 69.6 million viremic infections, thanks to increased treatment and prevention.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share

AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share | Hepatitis C New Drugs Review | Scoop.it
AbbVie's newly launched hepatitis C drug Mavyret has grabbed 7% of total new prescriptions, chipping away at Gilead's share.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks | AbbVie Newsroom

AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks | AbbVie Newsroom | Hepatitis C New Drugs Review | Scoop.it
NORTH CHICAGO, Ill., Aug. 3, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved MAVYRET™ (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Reliable Monitoring of Antiviral Therapy of Hepatitis C Infections

Reliable Monitoring of Antiviral Therapy of Hepatitis C Infections | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C (HCV) infection is the most common cause of liver cell carcinoma and liver transplants in Europe, which are possible late-stage effects of a chronic infection, alongside cirrhosis of the liver.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study

Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study | Hepatitis C New Drugs Review | Scoop.it
The management of patients with chronic hepatitis C (CHC) depends on their clinical stage. Thus, noninvasive early recognition of patients with CHC at high risk for developing liver-related events (LREs) is important because it ensures optimal preventative management strategies may be employed that can affect the course of CHC disease. Our aim was to determine whether liver stiffness measurement (LSM) in hepatitis C virus (HCV)-infected patients is associated with a risk of LREs, particularly in cirrhotic patients. We carried out a retrospective study on 343 HCV-infected patients stratified according to cirrhosis (LSM<12.5 kPa vs. LSM≥12.5 kPa), and the cirrhotic patient group (LSM≥12.5 kPa) was divided according to risk of esophageal varices (LSM <25 kPa vs. LSM≥25 kPa). For all patients, each incremental unit in the natural logarithm (Ln) of LSM was associated with 14.76 times higher risk of developing LREs (p<0.001). Patients with cirrhosis (LSM≥12.5 kPa) had a higher risk of LREs than patients without cirrhosis (LSM<12.5 kPa) [adjusted hazard ratio (aHR) = 30.97; p<0.001]. When only cirrhotic patients were analyzed (n = 60), each incremental unit in the Ln of LSM was associated with 10.56 times higher risk of developing LREs (p = 0.010). Patients with LSM≥25 kPa had a greater risk for LRE development compared to those with LSM<25 kPa (aHR = 3.65; p = 0.045). The AUROC for predicting the onset of LREs was 0.876 in all patients and 0.729 in cirrhotic patients. In conclusion, LSM was associated with an increased risk of developing LREs in HCV-infected patients, even within the group of cirrhotic patients.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Is elimination of hepatitis C from the UK by 2030 a realistic goal? | British Medical Bulletin | Oxford Academic

Is elimination of hepatitis C from the UK by 2030 a realistic goal? | British Medical Bulletin | Oxford Academic | Hepatitis C New Drugs Review | Scoop.it
AbstractIntroduction. Highly effective, combination therapy for chronic hepatitis C virus (HCV) infection is now available. Current cure rates are close to 100
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends

Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends | Hepatitis C New Drugs Review | Scoop.it
Janssen Sciences Ireland said Monday it would discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model

Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C is a liver disease caused by infection of the Hepatitis C virus (HCV). Many individuals infected by the virus are unable to resolve the viral infection and develop chronic hepatitis, which can lead to formation of liver cirrhosis and cancer. To understand better how initial HCV infections progress to chronic liver diseases, we characterised the long term pathogenic effects of HCV infections with the use of a humanised mouse model (HIL mice) we have previously established. Although HCV RNA could be detected in infected mice up to 9 weeks post infection, HCV infected mice developed increased incidences of liver fibrosis, granulomatous inflammation and tumour formation in the form of hepatocellular adenomas or hepatocellular carcinomas by 28 weeks post infection compared to uninfected mice. We also demonstrated that chronic liver inflammation in HCV infected mice was mediated by the human immune system, particularly by monocytes/macrophages and T cells which exhibited exhaustion phenotypes. In conclusion, HIL mice can recapitulate some of the clinical symptoms such as chronic inflammation, immune cell exhaustion and tumorigenesis seen in HCV patients. Our findings also suggest that persistence of HCV-associated liver disease appear to require initial infections of HCV and immune responses but not long term HCV viraemia.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Janssen to Discontinue Hepatitis C Development Program

Janssen to Discontinue Hepatitis C Development Program | Hepatitis C New Drugs Review | Scoop.it

CORK, Ireland, September 11, 2017 /PRNewswire/ -- Janssen to Discontinue Hepatitis C Development Program.


Janssen said it would not continue the development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals. The ongoing phase II studies with JNJ-4178 will be completed as planned, with no additional development thereafter, Janssen said in a statement on Monday.

Krishan Maggon 's insight:
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that on Saturday, September 9, 2017, it received notice of termination of the worldwide license and collaboration arrangement on hepatitis C with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The notice follows the decision by Janssen announced today to discontinue the development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals: AL-335, odalasvir and simeprevir.

the positive data presented in phase 2a with JNJ-41781, demonstrating a 100% cure rate after only six weeks of therapy,
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Virus I – Cellular and Molecular Virology PDF

Hepatitis C Virus I – Cellular and Molecular Virology PDF | Hepatitis C New Drugs Review | Scoop.it
Arslan Library is the ultimate source to Download Free Medical Books in PDF. This website has been designed especially for Medical Students & Doctors.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Peripheral T Cell Subpopulation in Patients with Hepatocellular Carcinoma: Relation to Ablation Therapy

Peripheral T Cell Subpopulation in Patients with Hepatocellular Carcinoma: Relation to Ablation Therapy | Hepatitis C New Drugs Review | Scoop.it
Background: Ablation therapy with advances in its techniques becomes widely used in patients with hepatocellular carcinoma. Ablative techniques can induce tumor cell deat..
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Res...

Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Res... | Hepatitis C New Drugs Review | Scoop.it
ABSTRACT Treatment for hepatitis C virus (HCV) has improved greatly through the use of direct-acting antivirals (DAAs). However, their effectiveness and potential for drug resistance development in non-genotype 1 variants of HCV remain relatively unexplored, as in vitro assays to assess drug susceptibility are poorly developed and unsuited for a transient-transfection format. In the current study, we have evaluated the effects of dinucleotide frequency changes in the replicon and the use of a SEC14L2-expressing cell line on the replication of HCVs of different genotypes and evaluated the resulting assay formats for measurements of susceptibility to the DAA sofosbuvir. Removal of CpG and UpA dinucleotides from the luciferase gene used in HCV replicons of genotype 1b (Con1) and genotype 2a (JFH-1) achieved between 10- and 100-fold enhancement of replication over that of the wild type posttransfection. Removal of CpG and UpA dinucleotides in the neomycin gene or deletion of the whole gene in replicons of genotype 3a (S52) and genotype 4a (ED43) enhanced replication, but phenotypic effects on altering luciferase gene composition were minimal. A further 10-fold replication enhancement of replicons from all four genotypes was achieved by using a transgenic Huh7.5 cell line expressing SECL14L2, whose expression showed a dose-dependent effect on HCV replication that was reversible by small interfering RNA (siRNA) knockdown of gene expression. By combining these strategies, the 100- to 1,000-fold enhancement of replication allowed the susceptibility of all four genotypes to the RNA polymerase inhibitor sofosbuvir to be robustly determined in a transient-transfection assay format. These methods of replication enhancement provide new tools for monitoring the susceptibility and resistance of a wide range of HCV genotypes to DAAs.
more...
No comment yet.